Drug intelligence / Profile preview

J65

Development stage: Phase 1
Lead developer: Walter Reed Army Institute of Research
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

J65 is a cytotoxic T-lymphocyte-eliciting peptide vaccine, an attenuated version of the E39 peptide. It is designed to stimulate an immune response against folate binding protein (FBP)-expressing cancer cells. The vaccine is restricted to HLA-A2+ patients and has been investigated in clinical trials for breast and ovarian cancer.

Targets

HLA-A2/FBP (HLA-A*02:01-restricted Folate Binding Protein peptide complex)

Beyond the preview

Go deeper on J65.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on J65.

Explore the full profile